Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
04 mai 2021 16h30 HE
|
Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
28 avr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
13 avr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: LIXT), a clinical-stage drug discovery company developing...
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
17 mars 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST...
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
03 mars 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma...
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
02 mars 2021 10h30 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
01 mars 2021 08h45 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
24 févr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma...
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
19 janv. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
01 déc. 2020 12h30 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: Common stock – LIXT; Warrants – LIXTW), a drug discovery company that uses...